Figure 4.

Inhibition of ¹²⁵I-RANTES complex binding to glycanase-treated PBMC by anti-CCR5 mAb 2D7. Normal human PBMC were activated as described previously and harvested on day 10 of culture to assay binding. Cells were treated with glycanase mixture for 1 hr. ¹²⁵I-RANTES was incubated with heparin (1 mg/ml) for 1 hr at 4°C. ¹²⁵I-RANTES complexes (0.3 nM RANTES component) were added to cells that had been treated with anti-CCR5 mAb 2D7 (10 μg/ml) (solid), normal mouse IgG (10 μg/ml) (striped), or PBS only (open). The values shown reflect the average of triplicate assays. SD values are shown with bars.